nafronyl has been researched along with Atrophy in 1 studies
Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Foit, A | 1 |
| Bischoff, W | 1 |
| Breinlinger, U | 1 |
| Kornhuber, HH | 1 |
1 other study available for nafronyl and Atrophy
| Article | Year |
|---|---|
Effects of naftidrofuryl on pathological EEG topography.
Topics: Adult; Aged; Atrophy; Brain Diseases; Cerebral Cortex; Double-Blind Method; Electroencephalography; | 1988 |